Oramed Pharma (ORMP)

$4.56 +0.11 (2.47%)
Market Cap 186.86M
Revenue (ttm) 2.00M
Net Income (ttm) 64.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 3,202.50%
Debt to Equity Ratio 0.00
Volume 179,795
Avg Vol 133,888
Day's Range N/A - N/A
Shares Out 40.45M
Stochastic %K 53%
Beta 1.27
Analysts Hold
Price Target $6.25

Company Profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New Y...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 967 2633
Website: oramed.com
Address:
1185 Avenue of the Americas, Third Floor, New York, United States
stockhom
stockhom May. 11 at 4:03 PM
$ORMP any news today?
2 · Reply
leimenbollen1
leimenbollen1 May. 11 at 3:11 PM
$ORMP financial release
0 · Reply
65creedmore
65creedmore May. 10 at 8:14 PM
$ORMP 👏
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 27 at 6:27 PM
$ORMP Share Price: $4.11 Contract Selected: Nov 20, 2026 $5 Calls Buy Zone: $0.47 – $0.58 Target Zone: $0.77 – $0.94 Potential Upside: 55% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Tazbro
Tazbro Apr. 13 at 8:26 PM
$ORMP What's today all about?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 13 at 6:16 PM
$ORMP RSI: 54.17, MACD: 0.0282 Vol: 0.14, MA20: 3.37, MA50: 3.32 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 12:49 AM
$ORMP Current Stock Price: $3.34 Contracts to trade: $2.5 ORMP Mar 20 2026 Call Entry: $0.70 Exit: $0.88 ROI: 25% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ZacksSCR
ZacksSCR Feb. 26 at 9:12 PM
$ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value https://buff.ly/JvC8ptp
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 8:52 PM
$ORMP RSI: 43.12, MACD: 0.0154 Vol: 0.12, MA20: 3.35, MA50: 3.12 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 20 at 4:44 PM
LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years $LFWD $ORMP https://stocktwits.com/news/equity/markets/lifeward-lfwd-stock-record-low/cZRNaRkR4xl
0 · Reply
Latest News on ORMP
Lifeward closes strategic partnership agreement with Oramed

2026-03-25T20:45:17.000Z - 6 weeks ago

Lifeward closes strategic partnership agreement with Oramed

LFWD

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Mar 13, 2026, 8:00 AM EDT - 2 months ago

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

LFWD

Oramed and Lifeward sign strategic transaction

2026-01-13T13:05:41.000Z - 4 months ago

Oramed and Lifeward sign strategic transaction

LFWD

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

Jan 13, 2026, 8:00 AM EST - 4 months ago

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

LFWD

Oramed and Lifeward Announce Strategic Transaction

Jan 13, 2026, 7:58 AM EST - 4 months ago

Oramed and Lifeward Announce Strategic Transaction

LFWD

Oramed receives $18M payment from Scilex Holdings

2026-01-07T14:02:48.000Z - 4 months ago

Oramed receives $18M payment from Scilex Holdings

Oramed declares cash dividend payment of 25c per share

2026-01-07T14:00:51.000Z - 4 months ago

Oramed declares cash dividend payment of 25c per share

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Jan 7, 2026, 8:55 AM EST - 4 months ago

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Oramed Reports Fiscal Third Quarter 2025 Financial Results

Nov 17, 2025, 8:56 AM EST - 6 months ago

Oramed Reports Fiscal Third Quarter 2025 Financial Results

Oramed declares dividend distribution of common stock purchase rights

2025-11-17T13:55:19.000Z - 6 months ago

Oramed declares dividend distribution of common stock purchase rights

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Nov 17, 2025, 8:50 AM EST - 6 months ago

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Oct 23, 2025, 8:55 AM EDT - 7 months ago

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Scilex completes first tranche of Oramed warrant repurchase

2025-10-01T13:05:56.000Z - 8 months ago

Scilex completes first tranche of Oramed warrant repurchase

SCLX

Alpha Tau enters strategic marketing alliance with Oramed

2025-04-28T13:15:07.000Z - 1 year ago

Alpha Tau enters strategic marketing alliance with Oramed

DRTS

Alpha Tau enters strategic marketing alliance with Oramed

2025-04-28T13:12:39.000Z - 1 year ago

Alpha Tau enters strategic marketing alliance with Oramed

DRTS

Oramed announces $36.9M investment and collaboration with Alpha Tau

2025-04-28T13:05:43.000Z - 1 year ago

Oramed announces $36.9M investment and collaboration with Alpha Tau

DRTS

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

DRTS

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

DRTS

Oramed Pharmaceuticals Issues Letter to Shareholders

Mar 4, 2025, 9:00 AM EST - 1 year ago

Oramed Pharmaceuticals Issues Letter to Shareholders

Oramed enters JV for insulin development and commercialization

2025-02-11T14:20:21.000Z - 1 year ago

Oramed enters JV for insulin development and commercialization

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Feb 11, 2025, 9:15 AM EST - 1 year ago

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

Scilex announces early installment payment on senior secured promissory note

2024-12-16T14:15:51.000Z - 1 year ago

Scilex announces early installment payment on senior secured promissory note

SCLX

Oramed announces restructuring of Scilex debt

2024-10-07T15:27:46.000Z - 1 year ago

Oramed announces restructuring of Scilex debt

SCLX

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

Oct 7, 2024, 10:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

SCLX

Oramed Letter to Shareholders

Jun 26, 2024, 9:05 AM EDT - 2 years ago

Oramed Letter to Shareholders

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Jun 26, 2024, 9:00 AM EDT - 2 years ago

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Sep 21, 2023, 6:11 PM EDT - 2 years ago

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Aug 2, 2023, 7:45 AM EDT - 3 years ago

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

Oramed to Present at the 83rd American Diabetes Association Conference

Jun 20, 2023, 7:55 AM EDT - 3 years ago

Oramed to Present at the 83rd American Diabetes Association Conference

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

May 18, 2023, 7:55 AM EDT - 3 years ago

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

May 15, 2023, 9:05 AM EDT - 3 years ago

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed Pharmaceuticals Issues Shareholder Update

Feb 9, 2023, 7:55 AM EST - 3 years ago

Oramed Pharmaceuticals Issues Shareholder Update

Oramed's oral insulin pill fails; stock is down 72%

Jan 12, 2023, 8:02 AM EST - 3 years ago

Oramed's oral insulin pill fails; stock is down 72%

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Jan 11, 2023, 8:00 PM EST - 3 years ago

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Jan 4, 2023, 7:55 AM EST - 3 years ago

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Nov 29, 2022, 8:40 AM EST - 3 years ago

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

Nov 18, 2022, 4:11 AM EST - 3 years ago

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Nov 14, 2022, 7:55 AM EST - 3 years ago

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Oramed Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 4:30 PM EST - 3 years ago

Oramed Reports Third Quarter 2022 Financial Results

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Nov 9, 2022, 8:40 AM EST - 3 years ago

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Oct 7, 2022, 8:40 AM EDT - 3 years ago

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Sep 13, 2022, 8:40 AM EDT - 3 years ago

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 7:55 AM EDT - 4 years ago

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Jul 26, 2022, 7:55 AM EDT - 4 years ago

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Jul 11, 2022, 7:55 AM EDT - 4 years ago

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Jun 1, 2022, 7:55 AM EDT - 4 years ago

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Oramed to Present at H.C. Wainwright Global Investment Conference

May 18, 2022, 7:55 AM EDT - 4 years ago

Oramed to Present at H.C. Wainwright Global Investment Conference

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

May 3, 2022, 8:10 AM EDT - 4 years ago

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Oramed Appoints Yadin Rozov to its Board of Directors

Apr 4, 2022, 8:25 AM EDT - 4 years ago

Oramed Appoints Yadin Rozov to its Board of Directors

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Mar 29, 2022, 8:25 AM EDT - 4 years ago

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Mar 22, 2022, 8:25 AM EDT - 4 years ago

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

Oramed to Present at Barclays Global Healthcare Conference

Mar 10, 2022, 8:25 AM EST - 4 years ago

Oramed to Present at Barclays Global Healthcare Conference

Oramed Issues Annual Message to Shareholders

Jan 12, 2022, 8:45 AM EST - 4 years ago

Oramed Issues Annual Message to Shareholders

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

Jan 5, 2022, 7:30 AM EST - 4 years ago

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Dec 29, 2021, 9:15 AM EST - 4 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Dec 29, 2021, 6:14 AM EST - 4 years ago

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Dec 29, 2021, 6:00 AM EST - 4 years ago

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Dec 14, 2021, 8:00 AM EST - 4 years ago

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Oramed Pharmaceuticals Appoints Chief Legal Officer

Dec 8, 2021, 7:30 AM EST - 4 years ago

Oramed Pharmaceuticals Appoints Chief Legal Officer

Oramed to Join MSCI USA Small Cap Index

Nov 24, 2021, 8:40 AM EST - 4 years ago

Oramed to Join MSCI USA Small Cap Index

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Nov 23, 2021, 8:25 AM EST - 4 years ago

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

Nov 18, 2021, 9:15 AM EST - 4 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

stockhom
stockhom May. 11 at 4:03 PM
$ORMP any news today?
2 · Reply
leimenbollen1
leimenbollen1 May. 11 at 3:11 PM
$ORMP financial release
0 · Reply
65creedmore
65creedmore May. 10 at 8:14 PM
$ORMP 👏
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 27 at 6:27 PM
$ORMP Share Price: $4.11 Contract Selected: Nov 20, 2026 $5 Calls Buy Zone: $0.47 – $0.58 Target Zone: $0.77 – $0.94 Potential Upside: 55% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Tazbro
Tazbro Apr. 13 at 8:26 PM
$ORMP What's today all about?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 13 at 6:16 PM
$ORMP RSI: 54.17, MACD: 0.0282 Vol: 0.14, MA20: 3.37, MA50: 3.32 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 12:49 AM
$ORMP Current Stock Price: $3.34 Contracts to trade: $2.5 ORMP Mar 20 2026 Call Entry: $0.70 Exit: $0.88 ROI: 25% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ZacksSCR
ZacksSCR Feb. 26 at 9:12 PM
$ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value https://buff.ly/JvC8ptp
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 8:52 PM
$ORMP RSI: 43.12, MACD: 0.0154 Vol: 0.12, MA20: 3.35, MA50: 3.12 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 20 at 4:44 PM
LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years $LFWD $ORMP https://stocktwits.com/news/equity/markets/lifeward-lfwd-stock-record-low/cZRNaRkR4xl
0 · Reply
DipTracker
DipTracker Feb. 18 at 10:15 AM
$ORMP Oral insulin biotech with long development timelines.
0 · Reply
chopnate
chopnate Feb. 10 at 12:31 PM
$ORMP is a biotech (Oramed) developing oral delivery for peptides; the technology is novel but faces significant scientific and regulatory hurdles.
0 · Reply
Stratsys
Stratsys Jan. 30 at 1:31 AM
$NNDM - New 13D filing ($ORMP) 🏢 Investor: ORAMED PHARMACEUTICALS INC. 💵 Avg Cost: $1.73 📦 Ownership: 5.0%
1 · Reply
BenYiju
BenYiju Jan. 25 at 1:07 AM
$MNKD Company has a real product (unlike outright scams like $ORMP) but the CEO and his crony hires hijack all the profits in egregious compensation and keeping a high rent headquarters in Corruptofornia instead of where all of the company’s real work is done back in CT. Good product, bad investment, criminal management. 👎
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 19 at 11:33 PM
$ORMP RSI: 84.22, MACD: 0.2235 Vol: 0.31, MA20: 2.97, MA50: 2.67 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JohnStocksNY
JohnStocksNY Jan. 14 at 12:09 PM
$ORMP Find someone that’ll care about you like this team cares about its investors
0 · Reply
JohnStocksNY
JohnStocksNY Jan. 13 at 3:16 PM
$ORMP and $LFWD Announce Strategic Transaction Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
0 · Reply
leimenbollen
leimenbollen Jan. 13 at 2:11 PM
$ORMP https://mailchi.mp/oramed/oramed-and-lifeward-announce-strategic-transaction?e=12a9ec4883
0 · Reply
Jaymuss
Jaymuss Jan. 10 at 11:07 PM
$ORMP What are the chances their MAA gets approved ?
0 · Reply
Gotalife
Gotalife Jan. 9 at 3:18 PM
$ORMP who doesn't love dividends even if it is a one time pay Oramed Pharmaceuticals Inc. (ORMP) recently declared a cash dividend of $0.25 per share. This is a one-time, special dividend rather than a recurring payment. Key Details of the Recent Dividend Dividend Amount: $0.25 per share. Ex-Dividend Date: January 16, 2026. Record Date: January 16, 2026 (shareholders on record as of this date are eligible). Payment Date: January 26, 2026. Total Distribution: Approximately $10.5 million in aggregate.
0 · Reply
Gotalife
Gotalife Jan. 9 at 3:12 PM
$ORMP Some additional DD. Oramed Pharmaceuticals Inc. (ORMP) recently declared a cash dividend of $0.25 per share. This is a one-time, special dividend rather than a recurring payment. Key Details of the Recent Dividend Dividend Amount: $0.25 per share. Ex-Dividend Date: January 16, 2026. Record Date: January 16, 2026 (shareholders on record as of this date are eligible). Payment Date: January 26, 2026. Total Distribution: Approximately $10.5 million in aggregate.
1 · Reply